Aspire Biopharma raises $2M via OID debentures

Aspire Biopharma Holdings, Inc. entered into a Securities Purchase Agreement with certain investors, issuing debentures with an aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000.

Rhea-AI Filing Summary

Aspire Biopharma Holdings, Inc. entered into a Securities Purchase Agreement with certain investors, issuing debentures with an aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000. The debentures carry an 8% original issue discount, bear no annual interest, and mature on April 23, 2026, or sooner if the company receives at least $8,000,000 in gross proceeds from any equity or debt financing within 90 days. The debentures are not convertible into common stock, and the company may prepay them at par with ten business days’ notice. In connection with this financing, investors also received 790,000 shares of common stock as incentive shares. The company plans to use the proceeds to pay down debt and for working capital.

Insights

Capital structure and credit analyst

Aspire Biopharma adds short-term non-convertible debt with equity incentives to refinance obligations.

Aspire Biopharma raised $2,000,000 through debentures with a principal amount of $2,173,913.04, structured as an 8% original issue discount and no ongoing interest. This brings immediate cash in while avoiding interest expense but creates a hard repayment obligation.

The debentures are due by April 23, 2026 or earlier once the company secures at least $8,000,000 in new equity or debt financing, concentrating refinancing and liquidity risk into a relatively short window. The option to prepay at par offers flexibility if cash flows or future financings allow.

Investors also received 790,000 incentive common shares, adding equity dilution to the capital structure. Proceeds are earmarked to repay existing debt and support working capital, so the net effect depends on how much higher-cost or nearer-term obligations this new financing replaces.

8-K Event Classification

3 items: 1.01, 3.02, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What financing did Aspire Biopharma (ASBP) announce in this 8-K?

Aspire Biopharma entered a Securities Purchase Agreement to issue debentures with a principal amount of $2,173,913.04 for a $2,000,000 subscription price. The deal adds short-term, non-convertible debt funding that the company intends to use for debt repayment and working capital needs.

What are the key terms of Aspire Biopharma’s new debentures?

The debentures have an 8% original issue discount, no annual interest, and mature on April 23, 2026. They are due earlier if Aspire Biopharma receives at least $8,000,000 in any equity or debt financing, and the company may prepay them at par with notice.

Are Aspire Biopharma’s new debentures convertible into common stock?

No, the debentures issued by Aspire Biopharma are explicitly described as not convertible into common stock. Instead of conversion rights, investors received 790,000 incentive shares of common stock alongside the debentures as part of the overall financing package.

How many Aspire Biopharma shares were issued as incentives in this financing?

Purchasers in the financing received an aggregate 790,000 shares of Aspire Biopharma common stock as incentive shares. These shares were granted in addition to the debentures and represent an equity component that may dilute existing shareholders depending on the company’s total shares outstanding.

How does Aspire Biopharma plan to use the $2,000,000 in proceeds?

Aspire Biopharma plans to use the debenture subscription proceeds to pay off debt and for working capital purposes. This suggests a focus on strengthening the balance sheet while also supporting ongoing operational funding needs in the near term.

Were Aspire Biopharma’s debentures and incentive shares registered with the SEC?

The debentures, referred to as Notes, were offered in reliance on Section 4(a)(2) of the Securities Act and were not registered. They may not be offered or sold in the United States without registration or a valid exemption from registration under applicable securities laws.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 05:05 PM EST Learn about SEC filing dates

false 0001847345 0001847345 2026-01-26 2026-01-26 0001847345 ASBP:CommonStockParValue0.0001PerShareMember 2026-01-26 2026-01-26 0001847345 ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember 2026-01-26 2026-01-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 26, 2026

ASPIRE BIOPHARMA HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-41293		33-3467744
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

23150 Fashion Drive, Suite 230
Estero, Florida		33928
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (908) 987-3002

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ASBP		The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of common stock		ASBPW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01- Entry into a Material Definitive Agreement

On January 26, 2026, Aspire Biopharma Holdings, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers certain debentures in an aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000 (the “Debentures”) with a maturity date of April 23, 2026. The Notes have an 8% original issue discount and do not bear any annual interest. The Debentures are due the sooner of (i) 90 days, or (ii) upon the Company’s receipt of gross proceeds of at least $8,000,000 in any equity or debt financing. The Company shall have the option to prepay this Debenture(s) at any time after the Original Issue Date at an amount equal to the Principal Amount. The Company shall provide Holder(s) with ten (10) Business Days’ prior written notice of intention to satisfy the Debentures, whether at maturity, by prepayment, or in default. The Debentures are not convertible into common stock. In connection with the financing the Purchasers received an aggregate of 790,000 Shares of the Company’s common stock as incentive shares.

The Notes were offered in reliance on Section 4(a)(2) of Securities Act of 1933, as amended (the “Securities Act”). The Notes were not, and will not be, registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, as applicable. The Company intends to utilize the proceeds to pay off debt and for working capital purposes.

The foregoing description of the Securities Purchase Agreement and the Debentures do not purport to be complete and are subject to, and qualified in its entirety by, the full text of each agreement, copies of which are attached hereto as Exhibits 10.1 and 10.2.

Item 3.02 Unregistered Sales of Equity Securities

See Item 1.01 above.

Item 9.01 Financial Statements and Exhibits.

d) Exhibits

Exhibit No.		Description
10.1		Form of Securities Purchase Agreement, dated January 26, 2026
10.2		Form of 8% OID Debenture, dated January 26, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ASPIRE BIOPHARMA HOLDINGS, INC.
Date:	January 30, 2026	By:	/s/ Kraig Higginson
			Kraig Higginson
			Chief Executive Officer